Search Result

Results for "

Farnesyl pyrophosphate

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Farnesyl Transferase (4) Adenosine Receptor (1) Apoptosis (8) Endogenous Metabolite (6) Isotope-Labeled Compounds (3) Parasite (5) Ras (1) TRP Channel (3) VEGFR (1)
By Research Areas:	Cancer (10) Infection (5) Inflammation/Immunology (1) Metabolic Disease (6) Neurological Disease (3)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Farnesyl Transferase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113037C

Farnesyl pyrophosphate ammonium Farnesyl diphosphate ammonium	TRP Channel Endogenous Metabolite	Neurological Disease
Farnesyl pyrophosphate ammonium salt, a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. Farnesyl pyrophosphate ammonium salt is a TRPM2 (TRP Channel) agonist, and activates TRPM2 opening for ion influx. Farnesyl pyrophosphate ammonium salt is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

HY-16011

NE 10790 1 Publications Verification 3-PEHPC	Farnesyl Transferase	Others
NE 10790, a poor farnesyl pyrophosphate synthase inhibitor, is a phosphonocarboxylate analogue of the potent bisphosphonate risedronate and is a weak antiresorptive agent.

HY-B0148

Risedronic acid 1 Publications Verification Risedronate	Parasite Apoptosis	Infection Metabolic Disease Cancer
Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC₅₀ of 20.3 μM) .

HY-113037B

**Farnesyl pyrophosphate** Farnesyl diphosphate	Endogenous Metabolite	Others
Farnesyl pyrophosphate is a key isoprenoid metabolite in the mevalonic acid (MVA) metabolic pathway. Farnesyl pyrophosphate is essential for proper localization and activation of proteins .

HY-113037AS

Farnesyl pyrophosphate-d6 Farnesyl diphosphate-d₆	Isotope-Labeled Compounds Endogenous Metabolite	Others
Farnesyl pyrophosphate-d₆ (Farnesyl diphosphate-d₆) is a deuterium labeled Farnesyl pyrophosphate (HY-113037B). Farnesyl pyrophosphate is a key isoprenoid metabolite in the mevalonic acid (MVA) metabolic pathway. Farnesyl pyrophosphate is essential for proper localization and activation of proteins .

HY-113037S1

Farnesyl pyrophosphate-d3 Farnesyl diphosphate-d₃	TRP Channel Endogenous Metabolite Isotope-Labeled Compounds	Neurological Disease
Farnesyl pyrophosphate-d₃ (Farnesyl diphosphate-d₃) is deuterium-labeled Farnesyl pyrophosphate (HY-113037) .

HY-113037

(E/Z)-Farnesyl pyrophosphate (E/Z)-Farnesyl diphosphate	TRP Channel Endogenous Metabolite	Neurological Disease
(E/Z)-Farnesyl pyrophosphate ((E/Z)-Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. (E/Z)-Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. (E/Z)-Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

HY-19301

J 104871 J-104135	Farnesyl Transferase	Cancer
J 104871 (J-104135) is a farnesyl pyrophosphate (FPP)-competitive farnesyltransferase (FTase) inhibitor. J 104871 inhibits rat brain FTase with an IC₅₀ of 3.9 nM in the presence of farnesyl pyrophosphate (FPP) .

HY-128041

alpha-Hydroxy farnesyl phosphonic acid HydroxyFarnesyl phosphate	Farnesyl Transferase	Others
α-hydroxy Farnesyl phosphonic acid is a nonhydrolyzable analog of farnesyl pyrophosphate which acts as a competitive inhibitor of farnesyl transferase (FTase). At concentrations greater than 1 μM, α-hydroxy farnesyl phosphonic acid inhibits the processing of Ras in Ha-ras-transformed NIH3T3 cells.

HY-W585869

Amorphadiene	Parasite	Infection
Amorphadiene is the precursor to the antimalarial agent artemisinin, which is produced through the amorphadiene synthase (ADS)-catalyzed cyclization of farnesyl pyrophosphate (FPP) yeast .

HY-B0119

Risedronic acid sodium 1 Publications Verification Risedronate sodium	Parasite Apoptosis	Infection Metabolic Disease Cancer
Risedronic acid (Risedronate) sodium, a bisphosphonate, is a potent anti-resorption agent that inhibits osteoclast-mediated bone resorption and changes the bone metabolism. Risedronic acid sodium suppresses osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis. Risedronic acid sodium inhibits blood stages of Plasmodium falciparum (IC₅₀ of 20.3 μM). Risedronic acid sodium inhibits the transfer of the farnesyl pyrophosphate group to parasite proteins .

HY-117012

NE58018	Endogenous Metabolite	Others
NE58018 is a compound with bone resorption inhibitory activity. NE58018 exerts its effect by affecting the action of Farnesyl pyrophosphate synthase (FPPS). The structural features of NE58018 combined with aminophosphonates significantly enhance its inhibitory activity. NE58018 affects the roles of Thr201 and Tyr204 residues in substrate binding and catalysis. The interaction of NE58018 enhances the inhibitory effect on the target enzyme .

HY-117807

A-176120	Ras Farnesyl Transferase VEGFR	Cancer
A-176120 is a selective inhibitor of farnesyl transferase (IC₅₀=1.2 nM) based on a farnesyl pyrophosphate (FPP) analog, with superior selectivity against GGTaseI (IC₅₀=423 nM), GGTaseII (IC₅₀=3000 nM), and SSase (IC₅₀>10 μM). A-176120 inhibits ras processing in H-ras transformed NIH3T3 cells and HCT116 K-ras mutant cells (ED₅₀=1.6 and 0.5 μM, respectively). A-176120 has antiangiogenic and antitumor activities in vivo and reduces capillary structure formation and VEGF secretion .

HY-B0148R

Risedronic acid (Standard) Risedronate (Standard)	Parasite Apoptosis	Infection Metabolic Disease Cancer
Risedronic acid (Standard) (Risedronate (Standard)) is the analytical standard of Risedronic acid (HY-B0148). This product is intended for research and analytical applications. Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC₅₀ of 20.3 μM).

HY-B0148S

Risedronic acid-d4 Risedronate-d₄	Isotope-Labeled Compounds Parasite Apoptosis	Infection Metabolic Disease Cancer
Risedronic acid-d₄ (Risedronate-d₄) is the deuterium labeled Risedronic acid (HY-B0148). Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC₅₀ of 20.3 μM) .

HY-B0515B

Ibandronate Sodium	Apoptosis	Metabolic Disease Cancer
Ibandronate Sodium is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium inhibits tumor cell proliferation (such as ER+ breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .

HY-B0515

Ibandronate Sodium Monohydrate BM-210955; RPR-102289A	Apoptosis	Metabolic Disease Cancer
Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium Monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium Monohydrate inhibits tumor cell proliferation (such as ER ⁺ breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium Monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .

HY-B0515R

Ibandronate Sodium Monohydrate (Standard) BM-210955 (Standard); RPR-102289A (Standard)	Apoptosis	Cancer
Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) (Standard) is the analytical standard of Ibandronate Sodium Monohydrate (HY-B0515). This product is intended for research and analytical applications. Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium Monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium Monohydrate inhibits tumor cell proliferation (such as ER ⁺ breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium Monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .

HY-N7844

N6-Benzyladenosine Benzyladenosine	Apoptosis Adenosine Receptor	Inflammation/Immunology Cancer
N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma ^- .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113037C

Farnesyl pyrophosphate ammonium Farnesyl diphosphate ammonium	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	TRP Channel Endogenous Metabolite
Farnesyl pyrophosphate ammonium salt, a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. Farnesyl pyrophosphate ammonium salt is a TRPM2 (TRP Channel) agonist, and activates TRPM2 opening for ion influx. Farnesyl pyrophosphate ammonium salt is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

HY-N7844

N6-Benzyladenosine Benzyladenosine	Natural Products Classification of Application Fields Eupatorium buniifolium Hook. & Arn. Source classification Umbelliferae Plants Phytohormone Inflammation/Immunology Disease Research Fields Cytokinin Cancer Agricultural Research	Apoptosis Adenosine Receptor
N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma ^- .

HY-113037

(E/Z)-Farnesyl pyrophosphate (E/Z)-Farnesyl diphosphate	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	TRP Channel Endogenous Metabolite
(E/Z)-Farnesyl pyrophosphate ((E/Z)-Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. (E/Z)-Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. (E/Z)-Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

HY-W585869

Amorphadiene	Structural Classification Microorganisms Terpenoids Sesquiterpenes Source classification	Parasite
Amorphadiene is the precursor to the antimalarial agent artemisinin, which is produced through the amorphadiene synthase (ADS)-catalyzed cyclization of farnesyl pyrophosphate (FPP) yeast .

Species:	Human (3) Mouse (1)
Tag:	His (4)
Source:	HEK293 (1) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P75197

	FDPS Protein, Human (His) Farnesyl pyrophosphate synthase; FPP synthase; FPS; KIAA1293	Human	E. coli
	FDPS Protein, a key enzyme in isoprenoid biosynthesis, catalyzes the formation of farnesyl diphosphate (FPP). FPP is a precursor for essential metabolites like sterols, dolichols, carotenoids, and ubiquinones. It also serves as a substrate for protein farnesylation and geranylgeranylation. FDPS sequentially condenses isopentenyl pyrophosphate with dimethylallyl pyrophosphate and then with geranylpyrophosphate to produce farnesyl pyrophosphate. FDPS Protein, Human (His) is the recombinant human-derived FDPS protein, expressed by E. coli , with N-His labeled tag.

HY-P75196

	FDPS Protein, Mouse (His) Farnesyl pyrophosphate synthase; FPP synthase; CR 39; Fdps	Mouse	E. coli
	FDPS proteins are key enzymes in isoprenoid biosynthesis and play a crucial role in the formation of farnesyl diphosphate (FPP). FPP is a precursor of essential metabolites involved in protein farnesylation and geranylgeranylation. FDPS Protein, Mouse (His) is the recombinant mouse-derived FDPS protein, expressed by E. coli , with N-His labeled tag.

HY-P70224

	GGPS1 Protein, Human (His) rHuGeranylgeranyl pyrophosphate synthase/GGPS1, His; Geranylgeranyl pyrophosphate Synthase; GGPP Synthase; GGPPSase; (2E; 6E)-Farnesyl Diphosphate Synthase; Dimethylallyltranstransferase; Farnesyl Diphosphate Synthase; Farnesyltranstransferase; Geranylgeranyl Diphosphate Synthase; Geranyltranstransferase; GGPS1	Human	E. coli
	The GGPS1 protein is responsible for catalyzing the trans-addition of three molecules of isopentenyl pyrophosphate (IPP) to dimethylallyl pyrophosphate (DMAPP) to synthesize geranylgeranyl pyrophosphate. This compound is an important precursor for the biosynthesis of carotenoids and geranylated proteins. GGPS1 Protein, Human (His) is the recombinant human-derived GGPS1 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P702577

	GGPS1 Protein, Human (HEK293, His) rHuGeranylgeranyl pyrophosphate synthase/GGPS1, His; Geranylgeranyl pyrophosphate Synthase; GGPP Synthase; GGPPSase; (2E; 6E)-Farnesyl Diphosphate Synthase; Dimethylallyltranstransferase; Farnesyl Diphosphate Synthase; Farnesyltranstransferase; Geranylgeranyl Diphosphate Synthase; Geranyltranstransferase; GGPS1	Human	HEK293
	The GGPS1 protein is responsible for catalyzing the trans-addition of three molecules of isopentenyl pyrophosphate (IPP) to dimethylallyl pyrophosphate (DMAPP) to synthesize geranylgeranyl pyrophosphate. This compound is an important precursor for the biosynthesis of carotenoids and geranylated proteins. GGPS1 Protein, Human (HEK293, His) is the recombinant human-derived GGPS1, expressed by HEK293 , with C-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-113037AS

Farnesyl pyrophosphate-d6
Farnesyl pyrophosphate-d₆ (Farnesyl diphosphate-d₆) is a deuterium labeled Farnesyl pyrophosphate (HY-113037B). Farnesyl pyrophosphate is a key isoprenoid metabolite in the mevalonic acid (MVA) metabolic pathway. Farnesyl pyrophosphate is essential for proper localization and activation of proteins .

HY-113037S1

Farnesyl pyrophosphate-d3
Farnesyl pyrophosphate-d₃ (Farnesyl diphosphate-d₃) is deuterium-labeled Farnesyl pyrophosphate (HY-113037) .

HY-B0148S

Risedronic acid-d4
Risedronic acid-d₄ (Risedronate-d₄) is the deuterium labeled Risedronic acid (HY-B0148). Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC₅₀ of 20.3 μM) .

Risedronic acid-d4

Risedronic acid-d₄ (Risedronate-d₄) is the deuterium labeled Risedronic acid (HY-B0148). Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC₅₀ of 20.3 μM) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks